🇺🇸 FDA
Patent

US 11634404

Selective D3 dopamine receptor agonists and methods of their use

granted A61PA61P25/14A61P25/16

Quick answer

US patent 11634404 (Selective D3 dopamine receptor agonists and methods of their use) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Apr 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61P, A61P25/14, A61P25/16, A61P25/28